Galapagos (GB:0JXZ) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Galapagos has announced promising results from its phase 1/2 study of the CD19 CAR T-cell therapy GLPG5101 in treating relapsed/refractory non-Hodgkin lymphoma, demonstrating high anti-tumor activity and a favorable safety profile. The study highlights the effectiveness of Galapagos’ decentralized manufacturing platform, which allows for the quick delivery of fresh CAR T-cells, achieving a vein-to-vein time of just seven days. These advances offer significant potential for improving patient outcomes in rapidly progressing cancers.
For further insights into GB:0JXZ stock, check out TipRanks’ Stock Analysis page.
